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Abstract 
 
Schizophrenia is a highly polygenic disorder with important contributions from both common 
and rare risk alleles. We analysed exome-sequencing data for de novo variants (DNVs) in a 
new sample of 613 schizophrenia trios, and combined this with published data for a total of 
3,444 trios. In our new data, loss-of-function (LoF) DNVs were significantly enriched among 
3,471 LoF intolerant genes, supporting previous findings. In the full dataset, genes associated 
with neurodevelopmental disorders (n=159) were significantly enriched for LoF DNVs. 
Within these neurodevelopmental disorder genes, SLC6A1, encoding a gamma-aminobutyric 
acid transporter, was associated with missense-damaging DNVs. In 1,122 trios for which we 
had genome-wide common variant data, schizophrenia and bipolar disorder polygenic risk 
were significantly over-transmitted to probands. Probands carrying LoF or deletion DNVs in 
LoF intolerant or neurodevelopmental disorder genes had significantly less over-transmission 
of schizophrenia polygenic risk than non-carriers, providing robust support for these DNVs 
increasing liability to schizophrenia. 
 
Introduction 
Genetic liability to schizophrenia involves a combination of rare and common risk alleles 
distributed across the genome1. Common schizophrenia risk alleles with odds ratios < 1.3 
account for at least a third of genetic liability2-4, although only a small fraction of this is 
captured by the 145 genome-wide significant loci that were implicated in the largest 
published genome-wide association study (GWAS) of the disorder5. At the other end of the 
frequency spectrum, rare copy number variants (CNVs) and rare coding variants, both 
sometimes occurring as de novo variants (DNVs), have been implicated in the disorder6-8. 
Although CNVs and rare coding variants are enriched in schizophrenia, not all rare variants 
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observed in individuals with schizophrenia, including those occurring de novo, are expected 
to be aetiologically relevant, as there is a baseline burden of these variants in the general 
population. 
 
In people with other neurodevelopmental disorders in which CNVs and rare coding variants 
play a role, particularly autism spectrum disorder (ASD)9,10 and developmental delay11,12, the 
enrichment for rare coding variants is greatest in genes classified as intolerant to loss-of-
function (LoF) variants (i.e. variants that introduce premature stop codons or frameshifts in 
the encoded protein, or are predicted to disrupt mRNA splicing). This indicates that rare 
coding variants in these genes are more likely to be pathogenic for those disorders than rare 
coding variants occurring elsewhere in the genome. Moreover, greater enrichment is found 
for LoF DNVs than for missense DNVs that change an encoded amino acid, indicating the 
former class of mutation is particularly likely to be pathogenic. Similar observations have 
been made in schizophrenia, where an excess of LoF DNVs was found to be largely restricted 
to LoF intolerant genes7, although the degree of enrichment is lower than for ASD or 
developmental disorders.  
 
In studies of ASD and developmental disorders, a significant excess of rare coding variants 
has been observed for 99 and 93 genes, respectively, with 33 of these genes overlapping 
between these disorders9,11. Only two genes, SETD1A13 and RBM1214, are currently 
associated with rare coding variants in schizophrenia. This is partly because of lower 
statistical power, as the number of trios that have been exome-sequenced in studies of 
schizophrenia (n=2,834) is smaller than equivalent studies of developmental disorders 
(n=7,580)11 and ASD (n = 6,430)9, but it also reflects the weaker enrichment in schizophrenia 
for this type of variant. As a set, genes disrupted by DNVs in neurodevelopmental disorders  
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are also enriched for DNVs in schizophrenia15,16, and therefore it follows that some of the 
genes implicated in ASD and developmental disorders by rare coding variants are also 
involved in the aetiology of schizophrenia. Aiming to contribute to the schizophrenia rare 
variant discovery effort, we have undertaken exome-sequencing in a new sample of 613 
schizophrenia trios, and combined our data with published data from 2,834 trios, which 
includes 617 trios previously sequenced by our group15, to provide the largest analysis of 
coding DNVs in schizophrenia to date. Given the anticipated modest power even of this 
sample, as we have successfully done before for CNV analysis17, we exploited the well 
documented overlap in the genetic aetiologies of schizophrenia, ASD, and developmental 
disorders, to undertake a hypothesis focused analysis of neurodevelopmental disorder genes 
in schizophrenia, which highlights SLC6A1 as a novel risk gene. 
 
The involvement of common variant polygenic risk in schizophrenia is already 
established2,4,18, but few existing studies have empirically examined the relationships between 
different classes of rare and common variants. An early case-control exome sequencing study 
of schizophrenia found evidence for independent additive effects for common alleles, rare 
CNVs and rare coding variants when cases were compared with controls, but no within-case 
correlation between the burden of each type19. More recent evidence indicates a negative 
correlation within cases for schizophrenia-associated CNV carrier status and common risk 
variant burden, consistent with the hypothesis that the common and rare alleles co-act20,21. 
Thus, compared to controls, affected carriers of schizophrenia-associated CNVs have an 
increased  burden of common schizophrenia risk alleles as measured by the polygenic risk 
score (PRS)21, but in a within case analysis, this burden is inversely proportional to the 
estimated effect size of the implicated CNV20. In ASD and developmental disorders, common 
variant polygenic risk for those disorders has been shown to be over-transmitted from parents 
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to probands, but no difference has been reported between those that do or do not carry a 
disorder-associated DNV22,23. As yet, the relationship between de novo mutations and 
common allele risk has not been studied in schizophrenia. Here, we examine this relationship 
using the polygenic transmission-disequilibrium test (pTDT)23. Specifically, we show that 
people with schizophrenia who are carriers of DNVs in gene sets proposed to be relevant to 
schizophrenia have a lower common risk allele burden than people with schizophrenia who 
are not carriers.  
 
Results 
De novo mutation rates 
After variant quality control, we observed 606 coding de novo variants (DNVs) in 613 
probands, corresponding to a rate of 0.99 (s.e = 0.041) events per proband, which is not 
significantly different to the rate observed in a sample of 2,831 previously published 
schizophrenia trios (previous de novo rate = 1.004; rate ratio (95% confidence interval (CI)) = 
0.98 (0.9, 1.08); p = 0.74; Supplementary Table S1). Of the coding DNVs, 154 were 
synonymous, 372 were missense, 15 were inframe indels, 2 start-loss, 1 stop-lost, and 62 
were LoF (19 stop-gain, 13 splice and 30 frameshift indels). The number of coding DNVs 
observed per-trio followed the expected Poisson distribution (Supplementary Figure S4).  
 
De novo variant enrichment tests 
In the new data set, we observed a significant excess of LoF DNVs among LoF intolerant 
genes (Fig 1, rate ratio (95% CI) = 2.21 (1.3, 3.75); p = 2.3 × 10-3; Supplementary Table S2). 
Consistent with previous reports, we found no evidence for DNV enrichment in the following 
negative control gene set tests: LoF DNVs in LoF tolerant genes (Fig 1), synonymous DNVs 
in LoF intolerant genes; synonymous DNVs in LoF tolerant genes (Supplementary Table S3). 
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After combining the new trio data with previously published data from 2,831 trios, LoF 
DNVs were enriched in LoF intolerant genes with a rate ratio (95% CI) of 1.58 (1.28, 1.96) 
(p = 2.5 × 10-5) (Fig 1, Supplementary Table S2). Following review, we tested alternative 
definitions of LoF intolerant genes based on constraint metrics generated from the gnomAD 
dataset24; the degree of enrichment of LoF DNVs in schizophrenia is similar regardless of the 
definition of LoF intolerant genes (see Supplementary Material for full results).  
   
  
Figure 1. Gene set enrichment for loss-of-function de novo variants. Loss-of-function (LoF) 
DNVs were tested in LoF intolerant genes and neurodevelopmental disorder genes. For LoF 
intolerant and neurodevelopmental disorder gene sets, rate ratios and 95% confidence 
intervals are relative to the baseline DNV rate, which is defined as the LoF DNV enrichment 
observed for all genes outside of the given set. LoF DNV enrichment for LoF tolerant genes 
are shown as a negative control. A breakdown of the LoF intolerant and neurodevelopmental 
disorder gene set results is provided in Supplementary Tables S2 and S3. NDD = 
neurodevelopmental disorder.  
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In the combined trio data, no individual gene was significantly enriched for LoF DNVs after 
correction for all genes tested (n=19,109). The most significant novel gene was CUL1, which 
had two LoF DNVs in the new trios and one additional LoF DNV in the published trios 
(Table 1). 
 
Table 1 about here 
 
We have previously shown that rare CNVs that increase risk of schizophrenia are effectively 
confined to those that also influence other neurodevelopmental disorders17. Defining 
neurodevelopmental disorder genes as those (N=159) that are significantly enriched for rare 
coding variants in recent large studies of ASD9 and developmental disorders11, 
neurodevelopmental disorder genes were significantly enriched for LoF DNVs in the 
combined trio data (Fig 1; rate ratio (95% CI) = 3.3 (2.0, 5.17); p = 8.2 × 10-6; Supplementary 
Table S2), and this enrichment was significantly greater than for LoF intolerant genes (rate 
ratio (95% CI) = 2.37 (1.41, 3.8); p = 8.8 × 10-4). In the full sample of trios, we observed no 
enrichment of missense-damaging DNVs for sub-genic regions that have been identified as 
being depleted for missense variation25 (rate ratio (95% CI) = 1.004 (0.85,1.18); p = 0.9). The 
rate of missense-damaging DNVs in neurodevelopmental disorder genes was elevated 
compared with the background rate (rate ratio (95% CI) = 1.53 (0.79, 2.7)), but this is not 
significant (p = 0.16), possibly reflecting the small number of DNVs in neurodevelopmental 
disorder genes (n=13). 
 
Exploiting the strong enrichment among neurodevelopmental disorder genes for DNVs in 
schizophrenia, we undertook focused analysis of genes in this set, with the aim of identifying 
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high probability schizophrenia risk genes. As highlighted in the study of ASD9, association to 
some neurodevelopmental disorder genes is driven by LoF variants alone, a combination of 
LoF variants and missense variants, and in some cases, primarily by missense variants. 
Therefore, we considered all those classes of mutation in our analysis. All LoF/missense-
damaging DNVs observed in neurodevelopmental disorder genes and, where available, 
phenotypes observed in these carriers are presented in Supplementary Table S4.  
 
SLC6A1 was significantly associated with missense-damaging DNVs in our new trio data 
after correcting for three classes of mutation (LoF, missense-damaging and LoF plus 
missense-damaging) and 159 neurodevelopmental disorder genes (2 damaging-missense 
DNVs; p = 7.46 × 10-5; pcorrected = 0.036). This finding was supported in our analysis of all 
trio data, where we observed one additional missense-damaging DNV (Table 2; 3 missense-
damaging DNVs; p = 5.2 × 10-5, pcorrected = 0.025).  It is striking that in the study of ASD
9, 
association to SLC6A1 was also driven by missense variants (n=8) rather than LoF variants 
(n=1). Following the rationale outlined by the Deciphering Developmental Disorders Study26, 
we undertook a combined analysis of schizophrenia and ASD DNVs; the evidence for 
enrichment of missense-damaging DNVs (MPC ≥ 2) in SLC6A1 was more than 3 orders of 
magnitude stronger than for ASD alone, supporting the hypothesis that missense variants in 
this gene contribute to both disorders  (combined p = 1.6 × 10-14;  ASD alone p = 8.0 × 10-11). 
 
Table 2 about here 
 
Polygenic transmission disequilibrium tests  
Schizophrenia and BD PRS were significantly over-transmitted from parents to probands (Fig 
2, Supplementary Material Table S5). These results did not differ when the analysis was 
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restricted to trios with European ancestry (as defined by principal component analysis; 
Supplementary Material Table S5).  
 
 
 
Figure 2. Mean pTDT deviation and 95% confidence intervals for schizophrenia, bipolar 
disorder (BD), and height polygenic risk scores. Polygenic risk for schizophrenia and bipolar 
disorder is significantly over-transmitted to schizophrenia probands. PRS = polygenic risk 
score. 
 
Under a liability threshold model, probands carrying DNVs of large effect size should require 
less transmission of polygenic risk than probands without such a variant. To test this, the 
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mean pTDT was compared between carriers of candidate schizophrenia related DNVs and the 
remainder of the sample. We define candidate schizophrenia related DNVs as LoF DNVs in a 
LoF intolerant gene or a neurodevelopmental disorder gene. Given CNV deletions disrupting 
LoF intolerant genes are associated with schizophrenia7, we also included de novo CNV 
deletions disrupting one of these genes as candidate schizophrenia related DNVs (CNVs 
contributing to this analysis are presented in Supplementary Table S6. CNV calling 
procedure is outlined in the Supplementary Material).  
 
Probands carrying candidate schizophrenia related DNVs had a significantly lower mean 
pTDT than those who did not carry one of these DNVs (carrier mean pTDT (95% CI) = 0.07 
(-0.15, 0.29); non-carrier mean pTDT (95% CI) = 0.48 (0.43, 0.54); p = 3.5 × 10-4; Fig 3). 
Based on mean pTDT point estimates, the over-transmission of common risk alleles from 
parents is about 7-fold greater to non-carriers than carriers of candidate schizophrenia related 
DNVs, although this estimate is imprecise given the width of the confidence intervals (Fig 3). 
Similar patterns were observed when LoF and deletion DNVs were tested separately (Fig 3).  
In a negative control test, the mean pTDT did not significantly differ between probands 
carrying a synonymous DNV in either a LoF intolerant or neurodevelopmental disorder gene 
and non-carriers (Fig 3). 
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Figure 3.  Mean pTDT deviation and 95% confidence intervals for schizophrenia PRS. 
Results are shown for probands carrying various classes of de novo variant (DNV) in a LoF 
intolerant gene or a neurodevelopmental disorder gene; our primary analysis defined 
schizophrenia carriers as probands with a LoF or deletion DNV in a LoF intolerant gene or a 
neurodevelopmental disorder gene (LoF/deletion label). Results are also shown separately for 
carriers of LoF and deletion DNVs. LoF = loss-of-function.  
 
The finding that the mean pTDT deviation for schizophrenia PRS was significantly different 
between probands carrying candidate schizophrenia related DNVs and non-carrying probands 
was consistent across schizophrenia PRS training p-value thresholds (Supplementary Table 
S7). Although the pTDT method is expected to be robust to population stratification, the 
efficacy of PRS as a measure of relative liability varies with the extent to which the ancestry 
of the sample from which risk alleles are derived (the source GWAS) matches the ancestry of 
those being tested (in our case the trios). Given the source GWAS is primarily of European 
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ancestry, we tested, and confirmed, that our findings held when we restrict our analysis to 
trios with European ancestry (Supplementary Figure S5 and S6) despite the smaller sample 
size (all results for European-only trios are presented in Supplementary Tables S7 and S8).  
 
The mean pTDT in carriers of candidate schizophrenia related DNVs was not significantly 
greater than the null (Fig 3). Based on the pTDT standard deviation observed for 
schizophrenia PRS in all trios (0.89), we only had 80% power to detect a significant (alpha = 
0.05) mean pTDT of 0.4 in the 63 carriers of candidate schizophrenia related DNVs. Thus, 
while we can be confident that the over-transmission to candidate DNV carriers is less than to 
non-carriers, power limitations mean we cannot conclude that candidate DNV carriers have 
no contribution from common alleles. 
 
During the review process, we performed an exploratory analysis to evaluate whether pTDT 
was lower in carriers of additional classes of DNV. Despite testing a wide-range of 
alternative variant filters (e.g. excluding DNVs observed in ExAC/gnomAD), missense 
annotations (e.g. MPC scores and constrained coding regions), and CNVs intersecting only 
LoF tolerant genes, no set of DNV carriers had a significantly greater reduction in pTDT than 
that observed for our primary candidate schizophrenia-related set of DNVs defined above 
(see Supplementary Material Table S8 for all results).  
 
Discussion 
Proband-parent trio studies have identified large numbers of genes associated with DNVs in 
ASD and developmental disorders9,11. Although similar studies in schizophrenia have 
revealed general pathophysiological insights into the disorder, such as a role for proteins 
involved in postsynaptic signaling complexes15,27, schizophrenia gene discovery through 
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DNV analysis has been hindered by small samples. To add to efforts to overcome this 
limitation, we performed exome-sequencing of a new sample of 613 schizophrenia trios. We 
confirmed previous work showing schizophrenia LoF DNVs are significantly enriched 
among a set of 3,471 genes intolerant to this class of mutation, and identified a stronger 
enrichment of DNVs in a smaller set of 159 genes that are associated with rare coding 
variants in neurodevelopmental disorders. GWAS data suggest common risk alleles are under 
negative selection28 and enriched in highly conserved genes5, but are nevertheless maintained 
by population mechanisms related to background selection and genetic drift5,29. The findings 
from rare mutations, both CNVs7,30 and rare coding variants7,31, also support a role for 
deleterious point mutations in schizophrenia that are under more intense negative selection 
than alleles of weak effect. Despite this, the population burden of schizophrenia risk alleles 
seems to be maintained by mutation-selection balance; for CNVs, strong selection is balanced 
by their relatively high mutation rates30, while for exonic mutations, in the face of a low per 
base mutation rate, balance is likely maintained by the large size of the mutational target.  
 
In our analysis of all schizophrenia trios, no novel gene was unequivocally associated with 
DNVs after correction for all genes tested. Despite conducting the largest analysis of DNVs 
in schizophrenia to date, it is clear that even larger samples are required to identify specific 
risk genes with genome-wide levels of significance. However, taking an approach based on 
the wealth of data showing that rare CNVs that increase risk of schizophrenia are effectively 
confined to those that also influence other neurodevelopmental disorders17, and exploiting the 
observation here for strong enrichment for DNVs in known neurodevelopmental disorder 
genes, we find evidence for association between SLC6A1, which encodes a sodium-
dependent γ-aminobutyric acid (GABA) transporter (also known as GAT1), and missense-
damaging DNVs. SLC6A1 is involved in reuptake of the inhibitory neurotransmitter GABA 
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from the synaptic cleft; our finding therefore adds to the evidence for perturbation of 
GABAergic neuronal signaling in genetic risk for schizophrenia32. Congruent with our 
findings, the largest study of rare coding variants in ASD found SLC6A1 to be the most 
significant (of only four) genes where association signal was driven by missense-damaging 
variants (8 missense and 1 LoF DNVs)9. In myoclonic atonic epilepsy and developmental 
disorders, LoF variants account for 54% and 30% of the observed nonsynonymous DNVs, 
respectively9. Given the strong convergent evidence for this gene, and specifically for a role 
for missense mutations, from other neurodevelopmental disorders, SLC6A1 is highly likely 
also to be involved in schizophrenia. This conclusion is further supported by the result of the 
DNV missense meta-analysis of ASD and schizophrenia, in which the combined evidence for 
association is more than 3 orders of magnitude stronger than the (already strong) evidence for 
association to ASD alone, and surpasses genome-wide significance by 8 orders of magnitude.  
Given the small number of DNVs in SLC6A1, it will be important to extend our finding in 
other samples, and clearly, a larger number of DNVs will be required to establish that risk is 
conferred largely by missense rather than LoF mutations.   
 
The role of polygenic risk in schizophrenia has been widely studied using large case-control 
samples. However, to our knowledge, this is the first study to investigate polygenic risk in 
schizophrenia using the pTDT method. The pTDT method has several advantages over case-
control PRS studies as it is not confounded by ancestry or ascertainment bias or the 
possibility of effects arising from super-healthy controls in discovery GWAS and subsequent 
PRS test samples23. Our results provide strong refutation that such effects might explain the 
PRS effects that have been widely publicised in the literature, including that of overlap in risk 
between schizophrenia and BD.  
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More importantly in the present context, our finding that carriers of LoF DNVs in genes 
defined by LoF intolerance, or in a known neurodevelopmental disorder gene, have 
significantly lower distortion of transmission of polygenic liability from the mean parental 
PRS than do non-carriers provides orthogonal evidence that a substantial proportion of this 
class of de novo variant contribute to schizophrenia pathogenesis. This is an important 
observation given the possibility that previously documented gene set enrichments in cases of 
these variants could have been driven by errors in the calibration of the expected mutation 
rate, or technical issues arising from comparing cases and controls (or case and control trios) 
often derived opportunistically from different studies. 
 
Our limited sample size does not allow accurate estimation of the magnitude of difference in 
the transmission distortion between probands carrying candidate schizophrenia related DNVs 
and those that do not, but the point estimate is that the distortion in non-carriers is about 7-
fold of that of carriers (and almost 10-fold when restricted to those of European ancestry). 
This suggests that on average, the candidate DNVs contribute a substantial amount of  
liability in those who carry them. Indeed in the present study, carriers of candidate 
schizophrenia related DNVs did not significantly over-inherit a common allele burden from 
their parents, which is consistent with DNVs in LoF intolerant genes acting as monogenic 
risk factors in those who carry them. However, it is important to stress that the latter finding 
is also consistent with limited power (as discussed in the results) rather than no role for 
common variation in the carriers, and we note the point estimate for the pTDT in candidate 
DNV carriers is greater than 0. It will be important for future larger studies to determine 
whether differences in co-action between common and rare risk alleles exist between 
schizophrenia and neurodevelopmental disorders. Meanwhile, with respect to the genetic 
architecture of schizophrenia, together with previous findings from CNVs alone20,21, we 
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interpret our data as being consistent with a polygenic liability threshold model of 
schizophrenia33. 
 
In conclusion, we provide further evidence that certain classes of DNV are associated with 
increased risk for schizophrenia. We highlight strong evidence that mutations in SLC6A1, a 
known ASD, developmental disorders and epilepsy gene, confer high risk of schizophrenia. 
Through combining exome-sequencing and GWAS data, we show that carriers of candidate 
schizophrenia related DNVs inherit significantly fewer common risk alleles than non-
carrying cases, providing strong orthogonal evidence that these DNVs contribute to 
schizophrenia liability.  
 
Online Methods 
Sample overview 
674 schizophrenia proband-parent trios, consisting of 2,000 individuals, were exome-
sequenced on Illumina HiSeq 4000 platforms. The proband-parent trios were composed of 
653 trios, 9 quads (two affected children) and one family with 3 affected children. None of 
these samples have been previously exome-sequenced. The families were recruited by six 
independent groups (Supplementary Table S9), and were ascertained from general psychiatric 
wards or outpatient clinics. All probands had received a DSM-IV or ICD-10 diagnosis of 
schizophrenia or schizoaffective disorder. Individuals with a known diagnosis of 
intellectual disability or other neurodevelopmental disorder were not included.  For 
probands passing quality control (quality control procedure described below), information 
on family history of schizophrenia/psychosis was available for 552 trios; 66% of probands 
were recorded as family history negative. Further details on the recruitment and diagnostic 
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criteria for each cohort are provided in the Sample Description section of the Supplementary 
Material. 
 
Exome sequence generation 
Exome sequence was generated using the Nextera DNA Exome capture kit and HiSeq 
3000/4000 PE Cluster Kit and HiSeq 3000/4000 SBS Kit. Raw sequencing reads were 
processed according to GATK best practice guidelines34,35. Reads were aligned to the human 
reference genome (GRCh37) using bwa version 0.7.1536. Variants were called using GATK 
haplotype caller (v3.4) and filtered using the GATK Variant Quality Score Recalibration 
(VQSR) tool. For all samples passing quality control (criteria outlined below), we generated 
sequence data for a median of 83% of the exome target at ≥ 10X coverage. We discuss 
sequencing coverage further in the Supplementary Material. For future users of our new 
dataset, we provide in Supplementary Table S10 the median proportion each gene is covered 
at ≥ 10X coverage. 
 
Sample quality control 
Trios (n=27) were excluded for low sequencing coverage if less than 70% of the exome target 
achieved ≥10X coverage in the proband or either parent (Supplementary Figure S1). An 
additional 27 trios were excluded for excess heterozygosity (heterozygote:homozygote ratio > 
1.9) or evidence of cross sample contamination (as measured by the FREEMIX sequence 
only estimate of contamination37) (Supplementary Figure S2). The last two metrics are highly 
correlated. Identity-by-descent (IBD) analysis (plink v1.9) to ensure expected proband-parent 
relationships resulted in exclusion of 3 trios. Four additional trios were excluded as outliers 
for the number of DNVs (Supplementary Figure S3). Following implementation of all the 
above sample quality control steps, 613 proband-parent trios were retained for DNV analysis.  
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Variant quality control 
In each of our newly sequenced samples, we excluded genotypes if they did not meet the 
following criteria: depth ≥ 10X; genotype quality score ≥ 30; allele balance ≤ 0.1 and ≥ 0.9 
for homozygous genotypes for the reference and alternative allele, respectively; allele balance 
between 0.2 and 0.8 for heterozygous genotypes. For samples and variants that passed quality 
control, we observed no difference in the number of heterozygous variants transmitted or 
non-transmitted from parents to probands (transmission disequilibrium test p = 0.53), 
indicating high data quality.  
 
De novo variant calling 
Putative DNVs in the new trios were identified as sites that were heterozygous in the proband 
and homozygous for the reference allele in both parents. All trio members were required to 
pass genotype quality control described above. We considered as putative DNVs 1) those 
where there were no reads for the mutant allele in either parent, and the mutant allele was not 
called in any other sample of the new trios (parent or proband) and 2) those where the mutant 
allele met all of the following; an allele count ≤3 in all newly sequenced samples, no mutant 
allele variant reads in either parent, and at least 5 reads of the mutant allele in the proband. 
Read alignments for all putative DNVs were manually inspected using IGV 
(http://software.broadinstitute.org/software/igv/) and variants were reassigned as high or low 
confidence if there was, respectively, no evidence or evidence for, read misalignment.  
 
We used Sanger sequencing to perform a validation experiment, where DNA was available 
and primers could be designed, on all high confidence LoF DNVs, as well as additional 
putative DNVs. In total, primers were successfully designed for 205 putative DNVs. We 
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observed high validation rates for high confidence DNVs (95.5%) and low rates (3.4%) for 
low confidence DNVs (Supplementary Table S11). Following these results, in our new trios 
we included in the downstream analyses all high confidence DNVs (N = 606 coding DNVs, 
Supplementary Table S12).  
 
Adding published de novo data 
To increase the power of our analysis, we included previously published DNVs from 2,831 
schizophrenia trios. When combined with our new trios, this resulted in a sample size of 
3,444 schizophrenia trios. We note that no DNV from our new trios was also observed among 
the previously published schizophrenia de novo data, thus confirming the independence of 
our new trio dataset. A summary of the published data can be found in Supplementary Table 
S13. 
 
De novo variant analysis 
We tested whether DNVs were enriched in single genes or sets of genes using the statistical 
framework described in Samocha et al 201438. Here, for a given set of genes we estimated the 
number of DNVs expected in our new sample using per-gene mutation rates39, adjusted for 
sequence coverage. When estimating the number of expected DNVs in previously published 
trios, we did not adjust per-gene mutation rates for coverage as coverage metrics were not 
available for all samples; the use of unadjusted per-gene mutation would over-estimate the 
expected number of DNVs in these trios, producing more conservative enrichment results. 
For our gene-set analysis, we define LoF intolerant genes as genes with a pLi score  0.9, 
using pLi metrics generated from the non-psychiatric component of ExAC31 (available from 
http://exac.broadinstitute.org/downloads). For single genes, we tested whether the overall 
burden of DNVs was significantly greater than that expected using a one-sided Poisson test 
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(implemented in R). For our primary de novo gene set analysis, we controlled for background 
de novo rates by using a two-sample Poisson rate ratio test, which compared the DNV 
enrichment observed for genes in the set to that in genes outside the set.  
 
DNVs from both the new trios and previously published de novo data were annotated using 
Ensemble Variant Effect Predictor (version 96)40. We define LoF variants as stop-gain, 
splice-acceptor, splice-donor and frameshift mutations. Although we observed a small 
number of start-loss and stop-loss DNVs, we did not include them in our LoF annotation as 
mutation rates are not available for these variants. We classify missense-damaging variants as 
missense variants with an MPC score ≥ 2, as this metric has proven effective at identifying 
variants associated with ASD9,25. Missense-damaging mutation rates for individual genes 
were calculated by summing tri-nucleotide mutation probabilities for all sites with an MPC 
score ≥ 2. Following previous work by us and others15,16, if an individual carried multiple de 
novo variants in the same gene, we conservatively considered these to be the result of a single 
mutation event, and retained for analysis only the variant predicted to be most deleterious. 
 
Polygenic risk scores 
Where available (n=1,122 trios), we used SNP genotype data to generate polygenic risk 
scores. We confirmed that genotype and exome-sequence data belonged to the same 
individual through IBD analysis (plink v1.9). A summary of the data sets for which we had 
both exome-sequencing and SNP genotype data can be found in Supplementary Table S14. 
To derive PRS for schizophrenia, bipolar disorder (BD) and height, we used the largest 
available GWAS summary statistics that were independent from our trio test data. Given 
some samples overlapped between our Bulgarian trios and PGC2, we computed 
schizophrenia PRS in the Bulgarian trios using custom PGC2 GWAS summary statistics that 
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omitted the Bulgarian samples. We used BD PRS as previous studies have shown that 
common variant liability to schizophrenia and BD is substantially shared41. Height PRS was 
used as a negative control. A summary of the training data used to generate PRS can be found 
in Supplementary Table S14.  
 
For quality control purposes, SNP genotype data were first harmonised to the Haplotype 
Reference Consortium panel using the Genotype Harmonizer package42 and then subjected to 
standard quality control, which included exclusion of samples with a call rate < 95%, SNPs 
with a MAF < 0.1, SNPs with > 1% missingness, or SNPs with a Hardy-Weinberg 
equilibrium exact test p value < 1 × 10-6. PRS were generated using PRSice 2 software43, 
where SNPs were clumped based on a window of 250 kb and a maximum r2 of 0.2.  We 
generated PRS across a range of training data P-value thresholds (P < 0.5, 0.1, 0.05, 0.001).  
 
pTDT deviation 
To test for a significant over-transmission of polygenic risk, we used the polygenic 
transmission disequilibrium test (pTDT) as described in Weiner et al (2017)23. Here, pTDT 
deviation scores were generated for each trio by subtracting the mean-parental PRS from the 
child PRS (Equation 1). pTDT deviation scores were standardised by dividing them by the 
cohort-specific mean-parental PRS standard deviation.  
 
𝑝𝑇𝐷𝑇 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =  
𝑃𝑅𝑆𝑝𝑟𝑜𝑏𝑎𝑛𝑑 − 𝑃𝑅𝑆𝑝𝑎𝑟𝑒𝑛𝑡𝑎𝑙 𝑚𝑒𝑎𝑛 
𝑆𝐷(𝑃𝑅𝑆𝑝𝑎𝑟𝑒𝑛𝑡𝑎𝑙 𝑚𝑒𝑎𝑛)
 
Equation 1. 
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We tested whether the mean pTDT deviation was significantly greater than 0, representing an 
over-transmission of polygenic risk, by using a one-sided one-sample t test. A one-sided two-
sample t test was used to compare mean pTDT deviation scores across groups of trios.   
 
The primary pTDT results were produced using PRS generated with a P-threshold of 0.05, as 
this threshold explained the most case-control variance in the 2014 schizophrenia PGC 
analysis4. However, we also present in the Supplementary Material Table S5 pTDT results 
obtained for PRS generated across different P-value thresholds. 
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Figure Legends 
 
Figure 1. Gene set enrichment for loss-of-function de novo variants. Loss-of-function (LoF) 
DNVs were tested in LoF intolerant genes and neurodevelopmental disorder genes. For LoF 
intolerant and neurodevelopmental disorder gene sets, rate ratios and 95% confidence 
intervals are relative to the baseline DNV rate, which is defined as the LoF DNV enrichment 
observed for all genes outside of the given set. LoF DNV enrichment for LoF tolerant genes 
are shown as a negative control. A breakdown of the LoF intolerant and neurodevelopmental 
disorder gene set results is provided in Supplementary Tables S2 and S3. NDD = 
neurodevelopmental disorder. 
 
Figure 2. Mean pTDT deviation and 95% confidence intervals for schizophrenia, bipolar 
disorder (BD), and height polygenic risk scores. Polygenic risk for schizophrenia and bipolar 
disorder is significantly over-transmitted to schizophrenia probands. PRS = polygenic risk 
score. 
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Figure 3.  Mean pTDT deviation and 95% confidence intervals for schizophrenia PRS. 
Results are shown for probands carrying various classes of de novo variant (DNV) in a LoF 
intolerant gene or a neurodevelopmental disorder gene; our primary analysis defined 
schizophrenia carriers as probands with a LoF or deletion DNV in a LoF intolerant gene or a 
neurodevelopmental disorder gene (LoF/deletion label). Results are also shown separately for 
carriers of LoF and deletion DNVs. LoF = loss-of-function.  
 
Tables 
 
Gene 
New trios  
(n=613) 
Published trios  
(n=2,831) 
All trios  
(n=3,444) 
LoF DNVs  P LoF DNVs  P LoF DNVs  P 
SETD1A 0 1 3 1.90E-06 3 3.00E-06 
CUL1 2 3.60E-05 1 0.04 3 2.00E-05 
TAF13 0 1 2 2.40E-05 2 3.30E-05 
GALNT9 0 1 2 2.90E-05 2 4.20E-05 
HENMT1 0 1 2 5.50E-05 2 7.90E-05 
PAF1 1 0.0028 1 0.013 2 0.00013 
SV2B 0 1 2 0.00016 2 0.00023 
NRXN3 0 1 2 0.00022 2 0.0003 
HIVEP3 0 1 2 0.00026 2 0.00035 
RB1CC1 0 1 2 0.00046 2 0.00065 
SMARCC2 0 1 2 0.0005 2 0.00068 
MKI67 0 1 2 0.00085 2 0.0012 
CHD8 0 1 2 0.0009 2 0.0013 
TENM1 1 0.0077 1 0.046 2 0.0014 
TRIO 0 1 2 0.0012 2 0.0016 
SCN2A 1 0.012 1 0.057 2 0.0024 
DNAH9 0 1 2 0.0018 2 0.0026 
KMT2C 0 1 2 0.0086 2 0.012 
KIAA1109 0 1 2 0.01 2 0.015 
TTN 1 0.16 2 0.22 3 0.092 
 
Table 1. Genes disrupted by 2 or more LoF de novo variants. The most significant gene, 
SETD1A, has been previously identified as a schizophrenia risk gene13. 
 
 
 
 31 
Gene 
Observed DNVs P (uncorrected) 
Missdam LoF Missdam + LoF Missdam LoF Missdam + LoF 
SLC6A1 3 0 3 5.20E-05* 1 7.90E-05* 
SCN2A 1 2 3 0.15 0.0024 0.0019 
SMARCC2 0 2 2 1 0.00068 0.0019 
PUF60 1 1 2 0.056 0.022 0.003 
MED13L 1 1 2 0.048 0.064 0.0062 
DEAF1 0 1 1 1 0.0082 0.011 
TRIO 0 2 2 1 0.0016 0.014 
CHD8 0 2 2 1 0.0013 0.023 
CHD4 1 1 2 0.2 0.04 0.03 
KMT2C 0 2 2 1 0.012 0.04 
PTEN 1 0 1 0.029 1 0.044 
GNAO1 1 0 1 0.042 1 0.052 
TEK 0 1 1 1 0.025 0.057 
AUTS2 0 1 1 1 0.03 0.057 
CSNK2A1 1 0 1 0.052 1 0.064 
POGZ 0 1 1 1 0.048 0.066 
NACC1 1 0 1 0.08 1 0.085 
KDM5B 0 1 1 1 0.084 0.092 
TLK2 1 0 1 0.075 1 0.1 
KDM6B 0 1 1 1 0.025 0.13 
GRIN2B 1 0 1 0.15 1 0.17 
SYNGAP1 0 1 1 1 0.026 0.21 
 
Table 2. Neurodevelopmental disorder genes with at least 1 LoF or missense-damaging de 
novo variant observed in schizophrenia. Enrichment P values are derived from the analysis of 
all schizophrenia trios (n = 3,444). Missdam = missense-damaging (MPC score ≥ 2). * indicate 
p values which survive correction for 159 neurodevelopmental disorder genes and three 
mutation classes (LoF, missense-damaging and LoF plus missense-damaging).  
 
